Our team was present at Advances Therapies Week in San Diego on February 9-12th, 2026.
Our takeaway is these six major key subjects the industry is clearly aligned on right now:
Standardization & automation are the number 1 priority. Closed systems, modular processes, digital batch records. Variability that the field can control is no longer acceptable.
CDMOs are strategic partners, not vendors. The transactional model is fading. Long-term alignment on risk and scale-up is the new expectation.
Cost og goods is a clinical constraint now. Payers are entering the conversation earlier. COGs can’t be a commercialization afterthought anymore.
Solid tumors and next-gen cell therapy are having a moment. The appetite for harder problems is real and competitive.
Investors want plateforms and scalable infrastructure. Single-asset companies face a much tougher pitch environment.
More partnerships, fewer big early VC rounds. Capital is being deployed more selectively than ever.
And the theme across all of it is: The science is there; Now it’s about execution and economics.
The C3i team recently wrapped up a busy week at the BIO International Convention in San Diego, where renewed investment, artificial intelligence, and cross-border collaboration set the tone for biotech in the year ahead. Three themes stood out on the show floor: A rebounding market. Investment is picking up across the biotech ecosystem, and with […]
For the first time in Canada, blood stem cells were genetically modified using CRISPR-Cas9 technology and subsequently injected into patients as part of a North American clinical trial targeting acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Every graft used in this landmark study was produced in Montreal, at HΓ΄pital Maisonneuve-Rosemont, through the biomanufacturing expertise […]
